olamufloxacin

04/01/1997 - "These results indicate that HSR-903 may be useful in the treatment of respiratory infections caused by chlamydiae."
10/01/2006 - "This study described distribution characteristics of olamufloxacin (HSR-903) in lung epithelial lining fluid (ELF) and alveolar macrophage (AM) in rats, two important representative infectious sites in lower respiratory tract infections. "
04/01/1998 - "These results indicate that clinical studies of HSR-903 against respiratory tract infections may be warranted."
07/01/1999 - "In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections."
04/01/1998 - "HSR-903 was active against experimental respiratory tract infections in mice challenged with penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and Haemophilus influenzae strains. "

07/01/2001 - "Olamufloxacin had equal efficacy for experimental urinary tract infections in mice caused by Pseudomonas aeruginosa."
07/01/2001 - "The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice."

12/01/2003 - "These data warrant further study of whether olamufloxacin is an option for the treatment of Legionella infections."
07/01/2001 - "Olamufloxacin was active against systemic infection in mice inoculated with both Gram-positive and -negative bacteria. "
12/01/2004 - "These results warrant the clinical effects of new types of fluoroquinolones, such as olamufloxacin, against respiratory tract and otolaryngology infections caused by ciprofloxacin-resistant H. "

12/01/2003 - "When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg. The 2 day post-infection bacterial burden of the lung in the animals treated with olamufloxacin (5 and 1.25 mg/kg given orally twice a day) was much lower than in those treated with levofloxacin (same dose as olamufloxacin) or erythromycin (10 mg/kg given orally twice a day). "
09/01/2000 - "Hokuriku is developing olamufloxacin, a quinolone antibiotic that inhibits DNA gyrase, for the potential treatment of various types of bacterial infection. "

04/01/1997 - "The therapeutic effect of HSR-903 in experimental mouse Chlamydia psittaci pneumonia was also excellent and almost equal to that of minocycline and superior to that of ofloxacin. "